Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Study of Brimonidine Tartrate Nanoemulsion Eye Drop Solution in the Treatment of Dry Eye Disease (DED)

ClinicalTrials.gov ID: NCT03785340

Public ClinicalTrials.gov record NCT03785340. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 9:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3 Randomized, Placebo-Controlled, Double-Masked, Multicenter, Safety and Efficacy Study of Brimonidine Tartrate 0.2% Nanoemulsion Eye Drops in Patients With Dry Eye Disease (DED)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study evaluates the use of Brimonidine tartrate nanoemulsion eye drop solution in the treatment of Dry Eye Disease (DED). Half of participants will receive Brimonidine and half will receive ophthalmic buffered saline (placebo).

Study identification

NCT ID
NCT03785340
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Ocugen
Industry
Enrollment
252 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 3, 2018 (Actual)
Primary completion
Feb 25, 2019 (Actual)
Completion
Feb 25, 2019 (Actual)
Last update posted
Jul 18, 2022

2018 – 2019

United States locations

U.S. sites
16
U.S. states
10
U.S. cities
14
Facility City State ZIP Site status
Aesthetic Eye Care Institute/David Wirta, MD and Associates Newport Beach California 92663 —
Martel Medical Eye Group Rancho Cordova California 95670 —
Rand Eye Institute Pompano Beach Florida 33064 —
Chicago Cornea Consultants Hoffman Estates Illinois 60169 —
Heart of America Eye Care, P. A. Mission Kansas 66204 —
Ophthalmology Associates St Louis Missouri 63131 —
Apex Eye- Kenwood Cincinnati Ohio 45236 —
Apex Eye-Montgomery Cincinnati Ohio 45242 —
Abrams Eye Center Cleveland Ohio 44115 —
Scott and Christie Eyecare Associates Cranberry Township Pennsylvania 16066 —
Total Eye Care Memphis Tennessee 38119 —
Toyos Clinic Nashville Tennessee 37215 —
Midtown Eye Physicans & Associates Houston Texas 77004 —
Advanced Laser Vision & Surgical Institute Houston Texas 77034 —
Revolution Research, Inc; Lake Travis Eye and Laser Center Lakeway Texas 78734 —
The Eye Institute of Utah Salt Lake City Utah 84107 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03785340, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 18, 2022 · Synced Oct 16, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT03785340 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →